Tocilizumab for severe and refractory mucous membrane pemphigoid.

Tedbirt B, Maho-Vaillant M, Gueudry J, Golinski ML, Marcaillou M, Bergeret B, Chambon G, Bouchetemble P, Bekri S, Tebani A, Maillard H, Morice C, Vautier A, Libert EP, Le Roux-Villet C, Carrette M, Boyer O, Hébert V, Calbo S, Gillibert A, Joly P

Open source

DOI: 10.1111/jdv.70510
Published: 2026 Oct
Container: Journal of the European Academy of Dermatology and Venereology : JEADV
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/jdv.70510,
  title = {Tocilizumab for severe and refractory mucous membrane pemphigoid.},
  author = {Tedbirt B and Maho-Vaillant M and Gueudry J and Golinski ML and Marcaillou M and Bergeret B and Chambon G and Bouchetemble P and Bekri S and Tebani A and Maillard H and Morice C and Vautier A and Libert EP and Le Roux-Villet C and Carrette M and Boyer O and Hébert V and Calbo S and Gillibert A and Joly P},
  year = {2026},
  journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
  doi = {10.1111/jdv.70510},
  url = {https://doi.org/10.1111/jdv.70510}
}

RIS

TY  - JOUR
TI  - Tocilizumab for severe and refractory mucous membrane pemphigoid.
AU  - Tedbirt B
AU  - Maho-Vaillant M
AU  - Gueudry J
AU  - Golinski ML
AU  - Marcaillou M
AU  - Bergeret B
AU  - Chambon G
AU  - Bouchetemble P
AU  - Bekri S
AU  - Tebani A
AU  - Maillard H
AU  - Morice C
AU  - Vautier A
AU  - Libert EP
AU  - Le Roux-Villet C
AU  - Carrette M
AU  - Boyer O
AU  - Hébert V
AU  - Calbo S
AU  - Gillibert A
AU  - Joly P
PY  - 2026
JO  - Journal of the European Academy of Dermatology and Venereology : JEADV
DO  - 10.1111/jdv.70510
UR  - https://doi.org/10.1111/jdv.70510
ER  -

APA

B, T., M, M., J, G., ML, G., M, M., B, B., G, C., P, B., S, B., A, T., H, M., C, M., A, V., EP, L., C, L. R., M, C., O, B., V, H., S, C., A, G., & P, J. (2026). Tocilizumab for severe and refractory mucous membrane pemphigoid.. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.70510

Source records

pubmed · retrieved 2026-09-26T22:50:22.305Z
europe-pmc · retrieved 2026-09-26T22:50:22.311Z
hal · retrieved 2026-09-26T22:50:22.334Z